UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine
ISSN 2079-0325(p)
DOI 10.36927/2079-0325
Home » Archive of numbers » 2022 » Volume 30, issue 4 (113) » CLINICAL PROTOCOL OF TERTIARY (HIGHLY SPECIALIZED) MEDICAL CARE FOR PATIENTS WITH MULTIPLE SCLEROSIS

CLINICAL PROTOCOL OF TERTIARY (HIGHLY SPECIALIZED) MEDICAL CARE FOR PATIENTS WITH MULTIPLE SCLEROSIS

Type of Article

  • Scientific Article

In the Section

  • CLINICAL PROTOCOLS
Index UDK:

Pages

  • 45-76

Year / Issue

Download PDF

References

  1. Boyko A. N. Choosing the optimal drug for the treatment of multiple sclerosis / A. N. Boyko // Medical Council. N. Selection of the optimal drug for the treatment of multiple sclerosis / A. N. Boyko // Medical Council. 2015. № 5. С. 78-86. DOI: https://doi.org/10.21518/2079-701X-2015-5-7-18.
  2. Boyko A. N. Choosing the optimal drug for pathogenetic treatment of multiple sclerosis: current state of the problem / A. N. Boyko. N. Choice of the optimal drug for pathogenetic treatment of multiple sclerosis: the current state of the problem / A. N. Boyko, O. V. Boyko, E. I. Gusev // Journal of Neurology and Psychiatry. С. С. Korsakov. 2014. № 10 (2). С. 77-91. URL: https://www.elibrary.ru/item.asp?id=22869449.
  3. Voloshina N. P. Strategies of multiple sclerosis treatment: effectiveness and safety / V. V. Vasilovsky, N. P. Voloshina, O. V. Egorkina // Ukrainian Medical Chasopis. 2012. NO. 4 (90) - VII/VIII. С. 32-36. URL: https://uvnpn.com.ua/upload/iblock/4c7/4c778f6cc0c5021e6941e6fca168fa8b.pdf.
  4. Clinical recommendations for the use of the drug alemtuzumab / V. M. Alifirova, G. N. Bisaga, A. N. Boyko [et al] // Journal of Neurology and Psychiatry. С. С. Korsakov. 2017. № 2 (2). С. 115-126. URL: https://www.ructrims.org/filesКлинические_рекомендации_по_применению_препарата_алемтузумаб_2018.pdf
  5. Clinical recommendations for the use of the drug dimethyl fumarate (Tekfidera) in relapsing-remitting multiple sclerosis / V. M. Alifirova, A. N. Boyko, Y. V. Vlasov [et al.] // Journal of Neurology and Psychiatry. С. С. Korsakov. 2017. № 1. С. 97-102. DOI: https://doi.org/10.17116/jnevro20171171197-102.
  6. Clinical recommendations for the use of the drug ocrelizumab in patients with multiple sclerosis / A. N. Boyko, M. V. Davydovskaya, N. V. Khachanova. [et al] // Neurology, neuropsychiatry, psychosomatics. 2019. № 11 (3). С. 16-25. DOI: https://doi.org/10.14412/2074-2711-2019-3-16-25.
  7. Clinical recommendations for the use of the drug teriflunomide / V. M. Alifirova, K. Z. Bakhtiyarova, A. N. Belova [et al.] // Journal of Neurology and Psychiatry. С. С. Korsakov. 2016. № 10 (2). С. 96-102. DOI: https://doi.org/10.17116/jnevro201611610298-104.
  8. Kobys T.O. Features of demyelinating process activity in patients with multiple sclerosis and ways of its correction / T.O. Kobys, O.A. Myalovytska, S. Sepekhri // Ukrainian Journal of Psychoneurology. 2010. Vol. 18, No. 3 (64). С. 84-85. URL: http://nbuv.gov.ua/UJRN/Uvp_2010_18_3_46.
  9. Cognitive profile of patients with multiple sclerosis / N. V. Litvinenko, V. A. Pinchuk, G. Y. Silenko [et al. Т. 16. № 3-4. С. 13-15. URL: https://cyberleninka.ru/article/n/kognitivniy-profil-patsientiviz-rozsiyanim-sklerozom.
  10. Criteria for ineffective therapy and withdrawal of first-line PITRS and replacement with second-line drugs // Journal of Neurology and Psychiatry. С. С. Korsakov. Special Issues. 2015. № 115, 8(2). С. 44. DOI: https://doi.org/10.17116/nevro20151158244.
  11. Lytvynenko N.V. Efficacy of neuromidine in the complex therapy of cognitive disorders in patients with relapsing-remitting multiple sclerosis / N.V. Lytvynenko, V.A. Pinchuk, G.Y. Silenko // Ukrainian Journal of Psychoneurology. 2013. Vol. 21, No. 4 (77). С. 130-132. URL: http://nbuv.gov.ua/UJRN/Uvp_2013_21_4_29.
  12. Myalovytska OA Peculiarities of the management of patients with multiple sclerosis in modern conditions / OA Myalovytska // International Neurological Journal. 2015. № 8. С. 26-32. URL: http://nbuv.gov.ua/UJRN/Mnzh_2015_8_6.
  13. Myalovytska OA Peculiarities of the management of patients with multiple sclerosis in modern conditions / OA Myalovytska // International Neurological Journal. 2015. № 8. С. 26-32. URL: http://nbuv.gov.ua/UJRN/Mnzh_2015_8_6.
  14. Prognostic assessment of the development of cognitive and emotional disorders in patients with multiple sclerosis depending on the localization of demyelination foci in the brain / O. A. Myalovytska, Y. V. Khyzhnyak // Ukrainian Neurological Journal. 2017. № 3. С. 33-37. URL: http://nbuv.gov.ua/UJRN/UNJ_2017_3_6.
  15. Order of the Ministry of Health No. 898 dated 11.02.2021 on promoting the implementation of measures to minimize the risks associated with the use of medicines, vaccines, tuberculin (clause 4.5 of the section). Approved by the State Enterprise "State Expert Center of the Ministry of Health of Ukraine": Additional measures to minimize risks of the medicinal product TACTROL (fingolimod).
  16. Negrich T.I. From probable diagnosis to effective therapy of multiple sclerosis / T.I. Negrich, B.V. Sorokin, S.G. Yevtushenko // International Neurological Journal. 2012. № 3 (49). C. 152-158. URL: http://www.mif-ua.com/archive/article/29729.
  17. Study of the effect of sol-medrol on the processes of apoptosis in multiple sclerosis / T. I. Negrych, R. S. Stoyka // Ukrainian Medical Journal. 2005. № 3 (47). V/VI. С. 54-56.
  18. Prevalence of polymorphisms of cytochrome p450 genes - metabolizers of warfarin - in Eastern Siberia / T. A. Bairova, E. A. Novikova, F. I. Belyalov [et al] // Acta Biomedica Scientifica (East Siberian Biomedical Journal). 2018; 3(5): 39-48. DOI: https://doi.org/10.29413/ABS.2018-3.5.6
  19. Recommendations on the use of cladribine in tablets for pathogenetic treatment of patients with highly active multiple sclerosis / K. Z. Bakhtiyarova, A. N. Boyko, Y. V. Vlasov [et al] // Neurology, Neuropsychiatry, Psychosomatics. 2020. № 12(3). С. 93-99. URL: https://nnp.ima-press.net/nnp/article/viewFile/1359/1050.
  20. Recommendations for the treatment of patients with active relapsing-remitting multiple sclerosis in Ukraine / L.I. Sokolova, T.I. Negrych, N.P. Voloshyna [et al. № 2. С. 93-96. DOI: https://doi.org/10.30978/UNZ2018293.
  21. Multiple sclerosis in Ukraine: a personalized treatment strategy / Muratova T.M., Negrych T.I., Voloshyna N.P. [et al. 2020. № 2. С. 14-16. URL: https://neuronews.com.ua/uploads/issues/2020/5(116)/nn20_5_54-57.pdf.
  22. Modern view on MRI diagnosis of multiple sclerosis: updated MRI criteria 2016 / V. V. Brukhov, I. A. Krotenkova, S. N. Morozova, M. V. Krotenkova // Journal of Neurology and Psychiatry. 2017. № 2. Iss. 2. С. 66-73. DOI: https://doi.org/10.17116/jnevro20171172266-73.
  23. Sokolova L. I. Comparative analysis of the effectiveness of differentiated treatment of multiple sclerosis in patients of different ages / L. I. Sokolova, M. M. Sepikhanova // Zb. nauk. prac. spivrobit. NMAPO imeni P. L. Shupik. 2014. № 23 (2). С. 289-297. URL: http://nbuv.gov.ua/UJRN/Znpsnmapo_2014_23%282%29__40.
  24. Sokolova L.I. Modern criteria for the diagnosis of multiple sclerosis in practical neurology / L.I. Sokolova // Ukrainian Journal of Psychoneurology. 2017. No. 25, issue 1 (90). С. 106-107. URL: http://nbuv.gov.ua/UJRN/Uvp_2017_25_1_83.
  25. Spirin N. N. N. Management of patients with multiple sclerosis : methodological recommendations / edited by Spirin N. N., Boyko A. N., Stepanov I. O., Schmidt T. E.. N. N., Stepanov I. O., Schmidt T. E. Moscow : ROOI "Human Health", 2015. 68 с.
  26. Voloshina N. P., Negreba T. V., Vasilovskiy V. V., Pesotskaya K. O., Chernenko M. E. Sravnitelnaya effektivnost gormonalnoy puls-terapii pri retsidiviruyushchem i vtorichno-progrediyentnom tipakh techeniya rasseyannogo skleroza s raznym kharakterom prognoza (Soobshcheniye II. Effektivnost gormonalnoy puls-terapii v debyutakh i na retsidiviruyushchem etape pri retsidiviruyushchem i vtorichno-progrediyentnom tipakh techeniya rasseyannogo skleroza s raznym kharakterom prognoza) [Comparative effectiveness of hormonal pulse therapy in relapsing and secondary progressive types of multiple sclerosis with different types of prognosis (Message II. Efficacy of hormonal pulse therapy in the onset and at the relapsing stage in relapsing and secondary progressive types of multiple sclerosis with different types of prognosis)]. Mіzhnarodniy nevrologіchniy zhurnal [International Neurological Journal]. 2018. № 7 (101). S. 11—16. (In Russian). http://nbuv.gov.ua/UJRN/Mnzh_2018_4_5; http://nbuv.gov.ua/UJRN/Mnzh_2018_7_4.
  27. Khabirov F. A. Multiple sclerosis: modern principles of diagnosis and treatment : a monograph / F. A. Khabirov, T. I. Khaibullin. Kazan : Medicine, 2017. 89 с.
  28. Analysis of clinical and paraclinical indicators in patients with multiple sclerosis with fatigue symptoms / Khyzhnyak Y. V., Myalovytska O. A., Nebor Y. Y. // Ukrainian Scientific and Medical Youth Journal. 2014. № 3. С. 105- 108. URL: http://nbuv.gov.ua/UJRN/Unmmj_2014_3_26.
  29. Holter monitoring of ECG during pulse therapy with methylprednisolone for exacerbations of multiple sclerosis / T. N. Muratova, V. V. Bugeruk, S. I. Drybina [et al.
  30. Effectiveness of betaferon in patients with an uncertain prognosis in the relapsing course of multiple sclerosis / V. V. Vasilovsky, N. P. Voloshina, T. V. Negreba [et al] // Ukrainian Vysnik Psychoneurologii. 2017. Vol. 25, v. 2 (91). С. 5-11. URL: http://nbuv.gov.ua/ UJRN/Uvp_2017_25_2_3.
  31. Effectiveness of mitoxantrone in patients with progredient types of multiple sclerosis course / N. P. Voloshina, V. V. Vasilovsky, T. V. Negreba, M. Є. Chernenko // International Neurological Journal. 2015. № 7(77). С. 17-27. URL: https://cyberleninka.ru/article/n/effektivnostmitoksantrona-u-bolnyh-s-progredientnymi-tipami-techeniyarasseyannogo-skleroza.
  32. Advances in the immunopathogenesis of multiple sclerosis  / S.  Yadav, J.  E.  Mindur, K.  Ito, S.  Dhib-Jalbut  // Curr Opin Neurol. 2015. №  28(3). Р.  19—20. DOI: https://doi.org/10.1097/WCO.0000000000000205.
  33. An observational study of alemtuzumab following fingolimod for multiple sclerosis / M. O. Willis Pearson, Z. Illes [et al.] // Neurol Neuroimmunol Neuroinflamm. 2017 Jan 10. No. 4(2). Р. 320. DOI: https://doi.org/10.1212/NXI.0000000000000320.
  34. Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response / M. Rotondi, M. Molteni, P. Leporati [et al.] // Front. Endocrinol. 2017. No. 8. Р. 254. DOI: https://doi.org/10.3389/fendo.2017.00254.
  35. Berkovich R. Effects of dimethyl fumarate on lymphocyte subsets / R. Berkovich, L. Weiner // Multiple Sclerosis and Related Disorders. 2015. № 4 (4). Р. 339—341. DOI: https://doi.org/10.1016/j.msard.2015.06.002.
  36. Claussen M. C. Immune mechanisms of new therapeutic strategies in MS: teriflunomide / M.    Claussen, T.  Korn  // Clin Immunol. 2012. No.  142. Р.  49—56. DOI: https://doi.org/10.1016/j.clim.2011.02.011.
  37. Confavreux C. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years / C. Confavreux, D. K. Li, M. S. Freedman // Mult Scler. 2012. No. 18(9). Р. 1278—1289. DOI: https://doi.org/10.1177/1352458512436594.
  38. Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study / J. T Phillips, A. A., Erwin, S. Agrella [et al.] // Neurology and Therapy. 2015. No. 4(2). Р. 137—146. DOI: https://doi.org/10.1007/s40120-015-0037-x.
  39. Coyle P. K. Management of women with multiple sclerosis through pregnancy and after childbirth / P. K. Coyle // Therapeutic Advances in Neurological Disorders. 2016. No. 9(3). Р. 198—210. DOI: https://doi.org/10.1177/1756285616631897.
  40. Dörr J. The transition from first-line to second-line therapy in  multiple sclerosis  / J.  Dörr, F.  Paul  // Curr Treat Options Neurol. 2015. No. 17(6). Р. 354—358. DOI: https://doi.org/10.1007/s11940-015-0354-5.
  41. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis / X. Montalban, R. Gold, A. J. Thompson [et al.] // Mult Scler. 2018 Feb; 24(2): 96—120. DOI: https://doi.org/10.1177/1352458517751049.
  42. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS) / R. Gold, G. Giovannoni, J. T. Phillips [et al.] // Multiple Sclerosis Journal. 2015. No. 21(1). Р. 57—66. DOI: https://doi.org/10.1177/1352458514537013.  DOI: https://doi.org/10.1177/1352458514537013.
  43. Evaluation of No Evidence of Progression (NEP) in Patients With Primary Progressive Multiple Sclerosis in the ORATORIO Trial. Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) / J. Wolinsky, X.  Montalban, D.    Arnold [et  al.]  // Forum 2017; February 23—25; Orlando, FL, USA. Poster P015.
  44. Freedman M. Severe, Highly Active, or Aggressive Multiple Sclerosis. / M.  Freedman, C.    Rush  // Continuum (Minneap Minn). 2016. No.  22. Р.  761—784. DOI: https://doi.org/10.1212/ CON.0000000000000331.
  45. Hands on Alemtuzumab-experience from clinical practice: whom and how to treat / L. Hassoun, J. Eisele, K. Thomas, T. Ziemssen // Multiple Sclerosis and Demyelinating Disorders. 2016. No. 1(1). DOI: https://doi.org/10.1186/s40893-016-0011-1.
  46. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome / Okuda D. T., Mowry E. M., Beheshtian A. [et al.] // Neurology. 2009 Mar 3; 72(9): 800—5. DOI: https://doi.org/10.1212/01.wnl.0000335764.14513.1a.
  47. Limsakun T. Pharmacokinetics of oral teriflunomide, a novel oral disease modifying agent under investigation for the treatment of multiple sclerosis / T. Limsakun, F. MenguyVacheron // Neurology. January 2010. 74: A415. 48. New EMA recommendations on Tecfidera // Reactions Weekly. 2015. No. 1576(1). 7  р. DOI: https://doi.org/10.1007/s40278-015-10164-9.
  48. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis / X.  Montalban, S.    Hauser, L.  Kappos [et al.] // N Engl J Med. 2017 Jan 19. No. 376(3). Р. 209—220. DOI: https://doi.org/10.1056/NEJMoa1606468.  Epub 2016 Dec 21.
  49. Prosperini L. Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations / L. Prosperini, S. Pontecorvo // Therapeutics and Clinical Risk Management. 2016. No. Р. 339—350. DOI: https://doi.org/10.2147/TCRM.S85099.
  50. Randomized trial of oral teriflunomide for relapsing multiple sclerosis / O’Connor, Wolinsky J., Confavreux C. [et al.] // The New England Journal of Medicine. 2011. No. 365. Р. 1293—1303. DOI: https://doi.org/10.1056/NEJMoa1014656.
  51. Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors / J. Zurawski, A. Flinn, L. Sklover, J. A. Sloane // Journal of Neurology. 2016. No. 263(8). Р. 1511—1517. DOI: https://doi.org/10.1007/s00415-016-8162-8.
  52. Rudick R. A. Current approaches to the identification management of breakthrough disease in patients with multiple sclerosis / R. A. Rudick, C. H. Polman // Lancet Neurology. 2009. No. 8(6). Р. 545—559. DOI: https://doi.org/10.1016/S1474-4422(09)70082-1.
  53. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study / Giovannoni Gavin, Per Soelberg Sorensen, Stuart Cook [et al.] // Multiple Sclerosis Journal. 2018. No. 24 (12). Р. 1594—1604. DOI: https://doi.org/10.1177/1352458517727603.
  54. Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis / L. Kappos, S. L. Hauser, X. Montalban [et al.] // MS & Demyelinating| Vol. 405, Suppl. 52, October 15, 2019. DOI: https://doi.org/10.1016/j.jns.2019.10.313.
  55. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis / A. Bar-Or, M. S. Freedman, M. Kremenchutzky [et al.] // Neurology. 2013. No. 81(6). Р. 552—558. DOI: https://doi.org/10.1212/WNL.0b013e31829e6fbf.
  56. The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro / L. Li, J. Liu, T. Delohery [et al.] // J Neuroimmunol. 2013. No. 265(1—2). Р. 82—90. DOI: https://doi.org/10.1016/j.jneuroim.2013.10.003.
  57. Updated Safety of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: Integrated Safety Analysis and Post-approval Data / Cook, G. Giovannoni, T. Leist [et al.] // Neurology. Apr 2020, 94 (15 Suppl.) 1656.
  58. Willis M. Alemtuzumab for the treatment of multiple sclerosis / N. Willis, M. Robertson // Therapeutics and Clinical Risk Management. 2015. No. Vol. 11. DOI: https://doi.org/10.2147/tcrm.s80112.

Journal’s Indexing:

UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine

ДУ «ІНПН імені
П.В. ВОЛОШИНА
НАМН УКРАЇНИ»